Harlan Laboratories, a privately held provider of general and specialty toxicology services through its Contract Research Services (CRS) business, and Fluofarma, a CRO specializing in high content analysis, have partnered to strengthen the companies’ drug discovery and translational medicine services.

Harlan CRS will utilize Fluofarma’s experience in high content analysis, biomarkers quantification and high content histology, including applications to mechanistic toxicology and prediction of toxicity.

“One of our goals is to help our customers reduce the risk of drug attrition during the development process,” said Ciriaco Maraschiello, director of strategic initiatives and director of drug discovery and translational medicine at Harlan CRS.